SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, announced today that it will present at the Jefferies 2016 Global Healthcare Conference taking place June 7-10, 2016 in New York City. David J. Bearss, Ph.D., Chief Executive Officer, is scheduled to present at 2:00 PM (EDT) and will answer questions in a breakout session at 2:30 PM (EDT) on Friday, June 10, 2016.
Tolero is currently initiating a multi-center randomized Phase 2 biomarker-driven clinical trial with their lead product alvocidib as part of a regimen with cytarabine, and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia (AML) (clinicaltrials.gov - NCT02520011). The trial will compare the above-referenced alvocidib-containing regimen to cytarabine and mitoxantrone alone in a biomarker-defined population of relapsed or refractory AML. The biomarker is intended to identify patients with a dependency on the cancer protein myeloid cell leukemia 1 (MCL-1). Alvocidib, a cyclin-dependent kinase-9 (CDK9) inhibitor, blocks transcription of MCL-1 and places AML cells in a heightened state of sensitivity to apoptosis-inducing agents.
Alvocidib is a potent small-molecule inhibitor of CDK9 in development as a combination therapy for frontline and relapsed/refractory AML. CDK9 is a protein critical to the regulation of gene expression including the MCL-1 gene and other important genes involved in cancer. Given the key role CDK9 de-regulation plays in expression of cancer-associated genes related to cell division and proliferation, CDK9 is an attractive target for the treatment of various cancers.
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.